Rady Venture Fund
VC Fund
La Jolla, United States
Rady Venture Fund is an evergreen fund. It specializes to invest in seed-to-early stage companies. It seeks to invest in life sciences and biotech including medical devices, instrumentation and diagnostics; high-tech; information technology; communication; water purification; and clean technology sectors. The fund prefers to invest in companiesbased in San Diego or Southern California. It makes equity investments ranging between $75,000 and $0.15 million. The fund prefers to invest in equity or provide debt financing, mostly in the form of convertible debt.
- Total investments:
- 4
- Last investment:
- Lead investor:
- 0%
Last updated:
For AI agents: llms.txt
Industries Rady Venture Fund invests in
Stages Rady Venture Fund invests in
Countries Rady Venture Fund invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Lada Rasochova
|
|||
Investment Focus
Industry
- SaaS 1 (25%)
- Sensor 1 (25%)
- Travel 1 (25%)
- Hardware 1 (25%)
- Software 1 (25%)
Stage
- Series B 3 (75%)
- Series A 1 (25%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Lada Rasochova
Managing Director
|
Managing Director | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Cloudbeds is a vertical SaaS business that creates cloud-based hospitality management software that simplifies the working lives of professional property owners, operators, and employees. It helps with OTAs, payments, reservations, and reporting so its clients can spend time on their most important job, taking care of their guests. Cloudbeds wasfounded in 2012 and is headquartered in San Diego, California. | $9M / Series B / Jun 22, 2017 | ||
| MANTA Instruments Inc. (MANTA) is commercializing scientific instruments that use breakthrough technology to characterize nanoparticles much more effectively than existing products. Existing instruments for characterizing nanoparticles are unable to: i) adequately measure concentration of nanoparticles, ii) measure samples with mixednanoparticle sizes, and iii) reliably measure changes in nanoparticle size over time. | Series A / Dec 10, 2015 | ||
| GroundMetrics, Inc is the world leader in the development of land-based EM sensing and is working with oil, gas, mining, and geothermal companies to commercialize a new class of sensor system and methods and to provide advanced survey and monitoring services worldwide. GroundMetrics, Inc. spun-out of QUASAR Federal Systems (QFS) in 2010 with anexclusive license to productize QFS’s novel electromagnetic sensor technology for resource exploration, management and production. This technology offers advanced capabilities for electromagnetic (EM), induced polarization (IP) magnetotelluric (MT), and controlled-source EM (CSEM) surveys in arid regions common in Australia, Canada, Mongolia, Mexico, the Middle East, South America and the United States. Furthermore, it improves the precision, safety and economics of Borehole-to-Surface (BSEM) surveys and is ideal for time-lapse and continuous long-term monitoring applications such as reservoir imaging and monitoring for Improved Oil Recovery (IOR) and Enhanced Oil Recovery (EOR). GroundMetrics uses its proprietary sensors, noise mitgation methods and focused-azimuth borehole transmitter technology to provide survey and monitoring services directly to energy and mining companies. | $1.5M / Series B / Apr 23, 2013 | ||
| Savara is an orphan lung disease company. Savara’s pipeline comprises Molgradex, an inhaled granulocyte-macrophage colony-stimulating factor, or GM-CSF, in Phase 3 development for autoimmune pulmonary alveolar proteinosis, or aPAP, in Phase 2a development for nontuberculous mycobacteria, or NTM, lung infection, and in preparation for Phase 2adevelopment in cystic fibrosis, or CF, affected individuals with chronic NTM lung infection; and AeroVanc, a Phase 3 stage inhaled vancomycin for treatment of persistent methicillin resistant staphylococcus aureus, or MRSA, lung infection in CF. Savara’s strategy involves expanding its pipeline of potentially best-in-class products through indication expansion, strategic development partnerships and product acquisitions, with the goal of becoming a leading company in its field. The most recent acquisition is aerosolized amikacin/fosfomycin, a Phase 2 ready, proprietary combination antibiotic, which has demonstrated potent and broad-spectrum antibacterial activity against highly drug resistant pathogens. Savara’s management team has significant experience in orphan drug development and pulmonary medicine, identifying unmet needs, developing and acquiring new product candidates, and effectively advancing them to approvals and commercialization. | Series B / Jun 13, 2012 |
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Rady Venture Fund invest in?
Rady Venture Fund invests primarily in SaaS, Sensor and Travel startups, most often at Series B and Series A stage. Most of the 4 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Rady Venture Fund?
Public channels for Rady Venture Fund include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Rady Venture Fund?
The team at Rady Venture Fund includes Lada Rasochova (Managing Director). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
